BCL-2 Is an Effective Target in Chronic Lymphocytic Leukemia
In her Diffusion article from the May/June issue of The Hematologist, Dr. Ann LaCasce (Dana-Farber Cancer Institute) discusses the use of the recently FDA-approved drug venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Dr. Andrew Roberts (Walter + Eliza Hall Institute of Medical Research) shares his thoughts about the drug and his experience with the first phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL/SLL in this thought-provoking conversation. You can find Dr. LaCasce’s Diffusion article online at www.hematology.org/Thehematologist/Diffusion/5479.aspx.
Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
In her Diffusion article from the May/June issue of The Hematologist, Dr. Ann LaCasce (Dana-Farber Cancer Institute) discusses the use of the recently FDA-approved drug venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Dr. Andrew Roberts (Walter + Eliza Hall Institute of Medical Research) shares his thoughts about the drug and his experience with the first phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL/SLL in this thought-provoking conversation. You can find Dr. LaCasce’s Diffusion article online at www.hematology.org/Thehematologist/Diffusion/5479.aspx.
Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
